Acromegaly is associated with high morbidity and elevated mortality when not adequately
treated. Surgery is the first-line treatment for most patients as it is the only one that can lead …

The delay in controlling the disease in patients who do not respond to first-line treatment
with first generation somatostatin receptor ligands (first-generation SRLs) can be quantified …

Background In 2007, we published an opinion document to review the role of pegvisomant
(PEG) in the treatment of acromegaly. Since then, new evidence emerged on the …

Acromegaly is a chronic disorder usually diagnosed late in the disease evolution. Such
delayed diagnosis, together with the inability to achieve the treatment goals of normalizing …

Acromegaly management is a significant challenge for endocrinologists. The Acromegaly
Consensus Group developed several statements on the management of acromegaly and …

Background Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA),
for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is …

Introduction Medical treatment of acromegaly is based in atrial and errorapproach. First-
generation somatostatin receptor ligands (fg-SRL) are prescribed as first-line medical …

Publisher Summary Acromegaly, a spectacular clinical syndrome of disordered somatic
growth and proportion, has intrigued physicians since earliest recorded history. It was …

abstract Context: There is concern that pegvisomant could be associated with a higher risk
of tumor growth. The rate and possible determinants of this tumor growth are unknown …

A significant proportion of total circulating growth hormone (GH) is bound to a high affinity
growth hormone binding protein (GHBP). Several low affinity binding proteins have also …